Both mechanisms may lead to direct and acute stimulation of lipolysis at peripheral tissues upon Rimonabant administration and represent targets for future obesity therapy which do not encompass the hypothalamic CB1R. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.